PDT Partners LLC Buys 388,817 Shares of Amicus Therapeutics, Inc. $FOLD

Key Points

• PDT Partners LLC increased its stake in Amicus Therapeutics by 110.3% during the first quarter, now holding 741,315 shares valued at approximately $6 million.
• Analysts have mixed ratings on Amicus Therapeutics, with eight analysts rating it as "Buy" and two as "Hold", while the consensus price target is set at $16.22.
• Shares of Amicus Therapeutics are currently trading at $7.59, with a market capitalization of $2.34 billion and a significant debt-to-equity ratio of 1.92.

PDT Partners LLC boosted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 110.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 741,315 shares of the biopharmaceutical company's stock after acquiring an additional 388,817 shares during the period. PDT Partners LLC owned approximately 0.24% of Amicus Therapeutics worth $6,049,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in FOLD. Raymond James Financial Inc. bought a new position in Amicus Therapeutics during the fourth quarter valued at about $132,000. Hsbc Holdings PLC increased its stake in Amicus Therapeutics by 82.6% during the fourth quarter. Hsbc Holdings PLC now owns 41,920 shares of the biopharmaceutical company's stock valued at $395,000 after acquiring an additional 18,964 shares during the period. Northern Trust Corp increased its stake in Amicus Therapeutics by 5.9% during the fourth quarter. Northern Trust Corp now owns 3,371,639 shares of the biopharmaceutical company's stock valued at $31,761,000 after acquiring an additional 187,652 shares during the period. Jane Street Group LLC increased its stake in Amicus Therapeutics by 7.8% during the fourth quarter. Jane Street Group LLC now owns 324,270 shares of the biopharmaceutical company's stock valued at $3,055,000 after acquiring an additional 23,524 shares during the period. Finally, Algert Global LLC increased its stake in Amicus Therapeutics by 64.0% during the fourth quarter. Algert Global LLC now owns 425,083 shares of the biopharmaceutical company's stock valued at $4,004,000 after acquiring an additional 165,923 shares during the period.

Amicus Therapeutics Price Performance

Shares of FOLD traded down $0.03 on Friday, hitting $7.99. The company's stock had a trading volume of 5,558,774 shares, compared to its average volume of 3,714,259. The company has a market capitalization of $2.46 billion, a PE ratio of -66.58 and a beta of 0.55. The company has a debt-to-equity ratio of 1.92, a current ratio of 3.21 and a quick ratio of 2.29. Amicus Therapeutics, Inc. has a fifty-two week low of $5.51 and a fifty-two week high of $12.65. The company has a 50 day moving average price of $6.74 and a 200 day moving average price of $7.06.

Analyst Upgrades and Downgrades

FOLD has been the topic of a number of recent research reports. Morgan Stanley raised Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a report on Thursday, July 17th. Wall Street Zen downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday, August 30th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat, Amicus Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $16.00.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.